Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Securing the academic pipeline amid uncertain U.S. funding climate
Finding creative ways to keep early-career researchers in academia—for example, through part-time roles—can help the field weather the storm.
Securing the academic pipeline amid uncertain U.S. funding climate
Finding creative ways to keep early-career researchers in academia—for example, through part-time roles—can help the field weather the storm.
Let’s teach neuroscientists how to be thoughtful and fair reviewers
Blanco-Suárez revamped the traditional journal club by developing a course in which students peer review preprints alongside the published papers that evolved from them.
Let’s teach neuroscientists how to be thoughtful and fair reviewers
Blanco-Suárez revamped the traditional journal club by developing a course in which students peer review preprints alongside the published papers that evolved from them.
New autism committee positions itself as science-backed alternative to government group
The Independent Autism Coordinating Committee plans to meet at the same time as the U.S. federal Interagency Autism Coordinating Committee later this month—and offer its own research agenda.
New autism committee positions itself as science-backed alternative to government group
The Independent Autism Coordinating Committee plans to meet at the same time as the U.S. federal Interagency Autism Coordinating Committee later this month—and offer its own research agenda.